Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study
Introduction: Tasisulam sodium (hereafter referred to as tasisulam) is a novel anticancer compound that induces apoptosis and exhibits antiangiogenesis activity in a broad range of cancer models, including non-small-cell lung cancer (NSCLC). Methods: Tasisulam was administered as a 2-hour infusion e...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Journal of thoracic oncology
Year: 2012, Jahrgang: 7, Heft: 6, Pages: 1053-1057 |
| ISSN: | 1556-1380 |
| DOI: | 10.1097/JTO.0b013e3182519d79 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1097/JTO.0b013e3182519d79 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1556086415332731 
|
| Verfasserangaben: | Giorgio V. Scagliotti, Robert Ilaria, Silvia Novello, J. von Pawel, Juergen R. Fischer, Sabine Ermisch, Dinesh P. de Alwis, Joan Andrews, Martin Reck, Lucio Crino, Corinna Eschbach and Christian Manegold |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581112343 | ||
| 003 | DE-627 | ||
| 005 | 20250827090801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180919s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JTO.0b013e3182519d79 |2 doi | |
| 035 | |a (DE-627)1581112343 | ||
| 035 | |a (DE-576)511112343 | ||
| 035 | |a (DE-599)BSZ511112343 | ||
| 035 | |a (OCoLC)1341018950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Scagliotti, Giorgio V. |e VerfasserIn |0 (DE-588)1077326319 |0 (DE-627)83633342X |0 (DE-576)446219193 |4 aut | |
| 245 | 1 | 0 | |a Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer |b a phase-II study |c Giorgio V. Scagliotti, Robert Ilaria, Silvia Novello, J. von Pawel, Juergen R. Fischer, Sabine Ermisch, Dinesh P. de Alwis, Joan Andrews, Martin Reck, Lucio Crino, Corinna Eschbach and Christian Manegold |
| 264 | 1 | |c 2012 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 20 November 2015 | ||
| 500 | |a Gesehen am 19.09.2018 | ||
| 520 | |a Introduction: Tasisulam sodium (hereafter referred to as tasisulam) is a novel anticancer compound that induces apoptosis and exhibits antiangiogenesis activity in a broad range of cancer models, including non-small-cell lung cancer (NSCLC). Methods: Tasisulam was administered as a 2-hour infusion every 21 days as third-line treatment in patients with advanced (stage IIIB/IV) NSCLC. Results: Thirty-two patients received a Cmax target dose of 420 µg/ml. Median time to progression was 3.12 months, median progression-free survival was 2.69 months, and median overall survival was 8.48 months. There were no objective responses; 43.8% of patients achieved stable disease. A high rate of grade-4 hematologic toxicity in the first 30 patients led to exploration of a lower Cmax target dose of 380 µg/ml. The rate of grade-4 hematologic toxicity (thrombocytopenia and/or neutropenia) at the 380-µg/ml dose (n = 20) was 20% versus 34% at the 420-µg/ml dose. The high rate of grade-4 hematologic toxicity observed with this highly albumin– bound compound in this patient population provided challenges for fixed Cmax-based dosing. Alternative dosing methods, including varying the Cmax target dose by predose albumin, are under investigation in other studies. Methods: Tasisulam was administered as a 2-hour infusion every 21 days as third-line treatment in patients with advanced (stage IIIB/IV) NSCLC. Results: Thirty-two patients received a Cmax target dose of 420 µg/ml. Median time to progression was 3.12 months, median progression-free survival was 2.69 months, and median overall survival was 8.48 months. There were no objective responses; 43.8% of patients achieved stable disease. A high rate of grade-4 hematologic toxicity in the first 30 patients led to exploration of a lower Cmax target dose of 380 µg/ml. The rate of grade-4 hematologic toxicity (thrombocytopenia and/or neutropenia) at the 380-µg/ml dose (n = 20) was 20% versus 34% at the 420-µg/ml dose. Conclusions: Tasisulam has only modest activity as a third-line treatment of patients with unresectable/metastatic NSCLC. The high rate of grade-4 hematologic toxicity observed with this highly albumin- bound compound in this patient population provided challenges for fixed Cmax-based dosing. Alternative dosing methods, including varying the Cmax target dose by predose albumin, are under investigation in other studies. | ||
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Non-small-cell lung cancer | |
| 650 | 4 | |a Phase II | |
| 650 | 4 | |a Tasisulam | |
| 700 | 1 | |a Eschbach, Corinna |e VerfasserIn |0 (DE-588)1084029723 |0 (DE-627)84823426X |0 (DE-576)456161449 |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology |d Amsterdam : Elsevier, 2006 |g 7(2012), 6, Seite 1053-1057 |h Online-Ressource |w (DE-627)508331986 |w (DE-600)2223437-8 |w (DE-576)336961553 |x 1556-1380 |7 nnas |a Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer a phase-II study |
| 773 | 1 | 8 | |g volume:7 |g year:2012 |g number:6 |g pages:1053-1057 |g extent:5 |a Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer a phase-II study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JTO.0b013e3182519d79 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1556086415332731 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180919 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |d 61800 |e 60000PM108614913 |e 61800PM108614913 |k 0/60000/ |k 1/60000/61800/ |p 12 |y j | ||
| 999 | |a KXP-PPN1581112343 |e 3025850299 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Scagliotti, Giorgio V.","given":"Giorgio V.","role":"aut","family":"Scagliotti"},{"display":"Eschbach, Corinna","family":"Eschbach","role":"aut","given":"Corinna"},{"family":"Manegold","given":"Christian","role":"aut","display":"Manegold, Christian"}],"title":[{"title_sort":"Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer","subtitle":"a phase-II study","title":"Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"5 S."}],"language":["eng"],"id":{"doi":["10.1097/JTO.0b013e3182519d79"],"eki":["1581112343"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"name":{"displayForm":["Giorgio V. Scagliotti, Robert Ilaria, Silvia Novello, J. von Pawel, Juergen R. Fischer, Sabine Ermisch, Dinesh P. de Alwis, Joan Andrews, Martin Reck, Lucio Crino, Corinna Eschbach and Christian Manegold"]},"recId":"1581112343","note":["Available online 20 November 2015","Gesehen am 19.09.2018"],"relHost":[{"part":{"text":"7(2012), 6, Seite 1053-1057","extent":"5","pages":"1053-1057","volume":"7","year":"2012","issue":"6"},"id":{"eki":["508331986"],"zdb":["2223437-8"],"issn":["1556-1380"]},"origin":[{"dateIssuedKey":"2006","publisher":"Elsevier ; Lippincott Williams & Wilkins","dateIssuedDisp":"2006-","publisherPlace":"Amsterdam ; Philadelphia, Pa."}],"disp":"Tasisulam sodium (LY573636 Sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer a phase-II studyJournal of thoracic oncology","recId":"508331986","title":[{"title_sort":"Journal of thoracic oncology","subtitle":"JTO ; official publication of the International Association for the Study of Lung Cancer","title":"Journal of thoracic oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2006 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JTO"}]}]} | ||
| SRT | |a SCAGLIOTTITASISULAMS2012 | ||